AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75N93020C00005MYELO THERAPEUTICS GMBH
Overview
Award facts
- Net obligations
- $6.73M
- $6,728,096of $6.73M potential value
- Outlays (paid to date)
- $5.39M
- $5.39M paid of $6.73M obligated$5,392,799
- Period of performance
- May 1, 2020 to Jan 16, 2025
- Ended
- Modifications
- 22
- Latest action Jan 16, 2025
- Contract type
- Definitive contract
- PIID 75N93020C00005
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME
Dates and value
- Award date
- Signed on Apr 30, 2020
- Potential end of performance
- Jan 15, 2025
- Current value
- $6,728,096Base and exercised options
- Potential value (if all options are exercised)
- $6,728,096
Obligations by fiscal year of action
- FY2023: $219,300
- FY2022: $1,996,255
- FY2021: $2,519,309
- FY2020: $1,993,232
Total across 4 fiscal years: $6,728,096
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Jan 16, 2025. View on USAspending · Recipient on SAM.gov
Recipient
LocationBERLIN, DEU
UEIG1LNCHNLYXF6
CAGE codeDP990
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeInternational org
Parent companyMYELO THERAPEUTICS GMBH
Business types and certifications
For-profit organizationInternational organizationLimited liability company
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- Nih office of the director (0846)Program activities075-0846Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Germany
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost plus fixed feeU
- Offers received
- 7
Solicitation and notices
- Solicitation ID
- HHS-NIH-NIAID-BAA2019-1
- Solicitation date
- Feb 22, 2019
- Notices
- Award Notice posted Aug 28, 2020
- Award Notice posted Aug 28, 2020
- Award Notice posted Jun 30, 2020
- Award Notice posted Jun 29, 2020
- Award Notice posted Jun 29, 2020
- Award Notice posted Jun 29, 2020
- Award Notice posted Jun 29, 2020
- Award Notice posted Apr 30, 2020
- Award Notice posted Apr 30, 2020
- Solicitation posted Aug 2, 2019
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Development of MYELO001 as an orally applied medical countermeasure for the treatment of hematopoiet
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Apr 30, 2020Base obligation at award: $1,993,232
- Latest action
- Jan 16, 2025 — Other administrative actionModification P00022; administrative: no change in scope or value
- Latest substantive action
- Apr 28, 2022 — Option exercisedModification P00010; obligation change +$1,996,255
- Latest funding action
- Sep 15, 2023 — Funding onlyModification P00017; obligation change +$219,300; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Other administrative action19
- Option exercised2
- Funding only1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- Foreign-owned business not incorporated in the U.S.D
- Country of product or service origin
- GermanyDEU
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 23
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2020/2020-0846-000
- 075-2021/2021-0846-000
- 075-2022/2022-0846-000
- 075-2023/2023-0846-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression